Pulmocide snags $30.4 mln Series B in SR One-led round
UK-based drug developer Pulmocide Ltd has closed $30.4 million in Series B financing. SR One led the round with participation from other investors that included Longwood Fund, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. and Touchstone Innovations plc.
21 March 2017•1 min read
